What is Curemark?
Curemark, LLC, through its wholly-owned subsidiary Galenagen, is dedicated to advancing treatments for a spectrum of neurological conditions. The company's therapeutic focus spans conditions such as autism, ADHD, addiction, schizophrenia, and Parkinson's disease. Galenagen specifically targets antibacterial and antiviral treatments, alongside medical devices, broadening Curemark's scope in the healthcare sector. The company's pipeline includes both preclinical and clinical-stage programs, indicating a commitment to innovation and addressing unmet medical needs in the biopharmaceutical space.
How much funding has Curemark raised?
Curemark has raised a total of $67.7M across 9 funding rounds:
Debt
$6M
Private Equity
$18.5M
Debt
$5M
Private Equity
$20.3M
Private Equity
$3M
Private Equity
$3.2M
Debt
$150K
Debt (2012): $6M, investors not publicly disclosed
Private Equity (2013): $18.5M, investors not publicly disclosed
Debt (2014): $5M, investors not publicly disclosed
Private Equity (2015): $20.3M, investors not publicly disclosed
Private Equity (2017): $3M, investors not publicly disclosed
Private Equity (2018): $3.2M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
What's next for Curemark?
With a substantial total funding of $67.7M and a recent strategic investment, Curemark is positioned for accelerated development and potential commercialization of its diverse pipeline. The company's focus on neurological disorders, a complex and often underserved area, suggests a long-term growth strategy. Future endeavors will likely involve advancing its clinical trials, potentially expanding its research into related therapeutic areas, and leveraging its subsidiary Galenagen's expertise in antibacterial, antiviral, and medical device development. This strategic financing will be crucial in navigating the rigorous path of drug development and regulatory approval, aiming to bring impactful therapies to patients.
See full Curemark company page
